Skip to main content
SpringerLink
Log in

Breast Cancer Management in the Era of Molecular Medicine: Tailored Radiotherapy — Clinical and Biological Aspects

  • Chapter
Breast Cancer and Molecular Medicine

  • 1005 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 189.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 249.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 329.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Leinster SJ: Impact of molecular biology on the clinical management of breast cancer. Biochem Soc Symp 63:185–91, 1998

    PubMed  CAS  Google Scholar 

  2. Schnitt SJ: Traditional and newer pathologic factors. J Natl Cancer Inst Monogr 30:22–6, 2001

    PubMed  Google Scholar 

  3. Hirano A, Utada Y, Haga S, et al: Allelic losses as prognostic markers for breast cancers. Int J Clin Oncol 6:6–12, 2001

    Article  PubMed  CAS  Google Scholar 

  4. Piccart M, Lohrisch C, Di Leo A, et al: The predictive value of HER2 in breast cancer. Oncology 61Suppl 2:73–82, 2001

    Article  PubMed  CAS  Google Scholar 

  5. Brenton JD, Aparicio SA, Caldas C: Molecular profiling of breast cancer: portraits but not physiognomy. Breast Cancer Res 3:77–80, 2001

    Article  PubMed  CAS  Google Scholar 

  6. Schnitt SJ: Can we identify patients with invasive breast cancer adequately treated with breast-conserving surgery alone? Mod Pathol 11:129–33, 1998

    PubMed  CAS  Google Scholar 

  7. Fisher B, Anderson S, Redmond CK, et al: Reanalysis and results after 12 years of follow-up in a randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med 333:1456–61, 1995

    Article  PubMed  CAS  Google Scholar 

  8. Clark RM, Whelan T, Levine M, et al: Randomized clinical trial of breast irradiation following lumpectomy and axillary dissection for node-negative breast cancer: an update. Ontario Clinical Oncology Group. J Natl Cancer Inst 88:1659–64, 1996

    Article  PubMed  CAS  Google Scholar 

  9. Silverstein MJ: Current management of noninvasive (in situ) breast cancer. Adv Surg 34:17–41, 2000

    PubMed  CAS  Google Scholar 

  10. Schwartz GF, Solin LJ, Olivotto IA, et al: Consensus Conference on the Treatment of In Situ Ductal Carcinoma of the Breast, April 22–25, 1999. Cancer 88:946–54, 2000

    Article  PubMed  CAS  Google Scholar 

  11. Nag S, Kuske RR, Vicini FA, et al: Brachytherapy in the treatment of breast cancer. Oncology (Huntingt) 15:195–202, 205; discussion 205–7, 2001

    PubMed  CAS  Google Scholar 

  12. Vicini FA, Chen PY, Fraile M, et al: Low-dose-rate brachytherapy as the sole radiation modality in the management of patients with early-stage breast cancer treated with breast-conserving therapy: preliminary results of a pilot trial. Int J Radiat Oncol Biol Phys 38:301–10, 1997

    Article  PubMed  CAS  Google Scholar 

  13. Recht A, Edge SB, Solin LJ, et al: Postmastectomy radiotherapy: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 19:1539–69, 2001

    PubMed  CAS  Google Scholar 

  14. Taylor ME, Haffty BG, Shank BM, et al: Postmastectomy radiotherapy. American College of Radiology. ACR Appropriateness Criteria. Radiology 215Suppl:1153–70, 2000

    PubMed  Google Scholar 

  15. Pietras RJ, Poen JC, Gallardo D, et al: Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene. Cancer Res 59:1347–55, 1999

    PubMed  CAS  Google Scholar 

  16. Cheng JC, Chen CM, Liu MC, et al: Locoregional recurrence in patients with one to three positive axillary nodes after mastectomy without adjuvant radiotherapy. J Formos Med Assoc 99:759–65, 2000

    PubMed  CAS  Google Scholar 

  17. Sundquist M, Thorstenson S, Klintenberg C, et al: Indicators of loco-regional recurrence in breast cancer. The South East Swedish Breast Cancer Group. Eur J Surg Oncol 26:357–62, 2000

    Article  PubMed  CAS  Google Scholar 

  18. Zellars RC, Hilsenbeck SG, Clark GM, et al: Prognostic value of p53 for local failure in mastectomy-treated breast cancer patients. J Clin Oncol 18:1906–13, 2000

    PubMed  CAS  Google Scholar 

  19. Fisher BJ, Perera FE, Cooke AL, et al: Long-term follow-up of axillary node-positive breast cancer patients receiving adjuvant systemic therapy alone: patterns of recurrence. Int J Radiat Oncol Biol Phys 38:541–50, 1997

    Article  PubMed  CAS  Google Scholar 

  20. Silvestrini R, Daidone MG, Luisi A, et al: Biologic and clinicopathologic factors as indicators of specific relapse types in node-negative breast cancer. J Clin Oncol 13:697–704, 1995

    PubMed  CAS  Google Scholar 

  21. Kurtz JM, Jacquemier J, Amalric R, et al: Why are local recurrences after breast-conserving therapy more frequent in younger patients? J Clin Oncol 8:591–8, 1990

    PubMed  CAS  Google Scholar 

  22. Harrold EV, Turner BC, Matloff ET, et al: Local recurrence in the conservatively treated breast cancer patient: a correlation with age and family history. Cancer J Sci Am 4:302–7, 1998

    PubMed  CAS  Google Scholar 

  23. de la Rochefordiere A, Asselain B, Campana F, et al: Age as prognostic factor in premenopausal breast carcinoma. Lancet 341:1039–43, 1993

    Article  PubMed  Google Scholar 

  24. Bartelink H, Horiot JC, Poortmans P, et al: Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation. N Engl J Med 345:1378–87, 2001

    Article  PubMed  CAS  Google Scholar 

  25. Elkhuizen PH, Voogd AC, van den Broek LC, et al: Risk factors for local recurrence after breast-conserving therapy for invasive carcinomas: a case-control study of histological factors and alterations in oncogene expression. Int J Radiat Oncol Biol Phys 45:73–83, 1999

    Article  PubMed  CAS  Google Scholar 

  26. Maher MG, Sapi E, Turner B, et al: Prognostic significance of colony-stimulating factor receptor expression in ipsilateral breast cancer recurrence. Clin Cancer Res 4:1851–6, 1998

    PubMed  CAS  Google Scholar 

  27. Santiago RJ, Wu L, Harris E, et al: Fifteen-year results of breast-conserving surgery and definitive irradiation for Stage I and II breast carcinoma: the University of Pennsylvania experience. Int J Radiat Oncol Biol Phys 58:233–40, 2004

    Article  PubMed  Google Scholar 

  28. DiPaola RS, Orel SG, Fowble BL: Ipsilateral breast tumor recurrence following conservative surgery and radiation therapy. Oncology (Huntingt) 8:59–68; discussion 71, 75–6, 1994

    PubMed  CAS  Google Scholar 

  29. Fowble B: Ipsilateral breast tumor recurrence following breast-conserving surgery for early-stage invasive cancer. Acta Oncol 38Suppl 13:9–17, 1999

    Article  PubMed  Google Scholar 

  30. Recht A: Selection of patients with early stage invasive breast cancer for treatment with conservative surgery and radiation therapy. Semin Oncol 23:19–30, 1996

    PubMed  CAS  Google Scholar 

  31. Provenzano E, Hopper JL, Giles GG, et al: Biological markers that predict clinical recurrence in ductal carcinoma in situ of the breast. Eur J Cancer 39:622–30, 2003

    Article  PubMed  CAS  Google Scholar 

  32. Agrup M, Stal O, Olsen K, et al: C-erbB-2 overexpression and survival in early onset breast cancer. Breast Cancer Res Treat 63:23–9, 2000

    Article  PubMed  CAS  Google Scholar 

  33. Pietras RJ, Fendly BM, Chazin VR, et al: Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene 9:1829–38, 1994

    PubMed  CAS  Google Scholar 

  34. Haffty BG, Brown F, Carter D, et al: Evaluation of HER-2 neu oncoprotein expression as a prognostic indicator of local recurrence in conservatively treated breast cancer: a case-control study. Int J Radiat Oncol Biol Phys 35:751–7, 1996

    Article  PubMed  CAS  Google Scholar 

  35. Pierce LJ, Merino MJ, D’Angelo T, et al: Is c-erb B-2 a predictor for recurrent disease in early stage breast cancer? Int J Radiat Oncol Biol Phys 28:395–403, 1994

    PubMed  CAS  Google Scholar 

  36. Ringberg A, Idvall I, Ferno M, et al: Ipsilateral local recurrence in relation to therapy and morphological characteristics in patients with ductal carcinoma in situ of the breast. Eur J Surg Oncol 26:444–51, 2000

    Article  PubMed  CAS  Google Scholar 

  37. Stal O, Sullivan S, Wingren S, et al: c-erbB-2 expression and benefit from adjuvant chemotherapy and radiotherapy of breast cancer. Eur J Cancer 31A:2185–90, 1995

    Article  PubMed  CAS  Google Scholar 

  38. Carr JA, Havstad S, Zarbo RJ, et al: The association of HER-2/neu amplification with breast cancer recurrence. Arch Surg 135:1469–74, 2000

    Article  PubMed  CAS  Google Scholar 

  39. Haffty BG, Hauser A, Choi DH, et al: Molecular markers for prognosis after isolated postmastectomy chest wall recurrence. Cancer 100:252–63, 2004

    Article  PubMed  Google Scholar 

  40. Zaugg K, Bodis S: Is there a role for molecular prognostic factors in the clinical management of ductal carcinoma in situ (DCIS) of the breast? Radiother Oncol 55:95–9, 2000

    Article  PubMed  CAS  Google Scholar 

  41. Ringberg A, Anagnostaki L, Anderson H, et al: Cell biological factors in ductal carcinoma in situ (DCIS) of the breast-relationship to ipsilateral local recurrence and histopathological characteristics. Eur J Cancer 37:1514–22, 2001

    Article  PubMed  CAS  Google Scholar 

  42. Perez EA, Roche PC, Jenkins RB, et al: HER2 testing in patients with breast cancer: poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization. Mayo Clin Proc 77:148–54, 2002

    Article  PubMed  Google Scholar 

  43. Ohta JI, Miyoshi Y, Uemura H, et al: Fluorescence in situ hybridization evaluation of cerbB-2 gene amplification and chromosomal anomalies in bladder cancer. Clin Cancer Res 7:2463–7, 2001

    PubMed  CAS  Google Scholar 

  44. Borg A, Lennerstrand J, Stenmark-Askmalm M, et al: Prognostic significance of p53 overexpression in primary breast cancer; a novel luminometric immunoassay applicable on steroid receptor cytosols. Br J Cancer 71:1013–7, 1995

    PubMed  CAS  Google Scholar 

  45. Buchholz TA, Weil MM, Story MD, et al: Tumor suppressor genes and breast cancer. Radiat Oncol Investig 7:55–65, 1999

    Article  PubMed  CAS  Google Scholar 

  46. Crook T, Crossland S, Crompton MR, et al: p53 mutations in BRCA1-associated familial breast cancer. Lancet 350:638–9, 1997

    Article  PubMed  CAS  Google Scholar 

  47. Jansson T, Inganas M, Sjogren S, et al: p53 Status predicts survival in breast cancer patients treated with or without postoperative radiotherapy: a novel hypothesis based on clinical findings. J Clin Oncol 13:2745–51, 1995

    PubMed  CAS  Google Scholar 

  48. Levesque MA, Katsaros D, Yu H, et al: Mutant p53 protein overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma. Cancer 75:1327–38, 1995

    Article  PubMed  CAS  Google Scholar 

  49. MacGrogan G, Bonichon F, de Mascarel I, et al: Prognostic value of p53 in breast invasive ductal carcinoma: an immunohistochemical study on 942 cases. Breast Cancer Res Treat 36:71–81, 1995

    Article  PubMed  CAS  Google Scholar 

  50. Silvestrini R: Re: the p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry. J Natl Cancer Inst 88:1499–500, 1996

    Article  PubMed  CAS  Google Scholar 

  51. Silvestrini R, Benini E, Veneroni S, et al: p53 and bcl-2 expression correlates with clinical outcome in a series of node-positive breast cancer patients. J Clin Oncol 14:1604–10, 1996

    PubMed  CAS  Google Scholar 

  52. Turner BC, Gumbs AA, Carbone CJ, et al: Mutant p53 protein overexpression in women with ipsilateral breast tumor recurrence following lumpectomy and radiation therapy. Cancer 88:1091–8, 2000

    Article  PubMed  CAS  Google Scholar 

  53. Amornmarn R, Bui MM, Prempree TB, et al: Molecular predictive factors for local recurrence and distant metastasis of breast cancer after lumpectomy with postoperative radiation therapy. Ann Clin Lab Sci 30:33–40, 2000

    PubMed  CAS  Google Scholar 

  54. Broet P, Romain S, Daver A, et al: Thymidine kinase as a proliferative marker: clinical relevance in 1,692 primary breast cancer patients. J Clin Oncol 19:2778–87, 2001

    PubMed  CAS  Google Scholar 

  55. Silvestrini R, Veneroni S, Benini E, et al: Expression of p53, glutathione S-transferase-pi, and Bcl-2 proteins and benefit from adjuvant radiotherapy in breast cancer. J Natl Cancer Inst 89:639–45, 1997

    Article  PubMed  CAS  Google Scholar 

  56. Turner BC, Haffty BG, Narayanan L, et al: Insulin-like growth factor-I receptor overexpression mediates cellular radioresistance and local breast cancer recurrence after lumpectomy and radiation. Cancer Res 57:3079–83, 1997

    PubMed  CAS  Google Scholar 

  57. Coco Martin JM, Balkenende A, Verschoor T, et al: Cyclin D1 overexpression enhances radiation-induced apoptosis and radiosensitivity in a breast tumor cell line. Cancer Res 59:1134–40, 1999

    PubMed  CAS  Google Scholar 

  58. Zhou Q, Fukushima P, DeGraff W, et al: Radiation and the Apo2L/TRAIL apoptotic pathway preferentially inhibit the colonization of premalignant human breast cells overexpressing cyclin D1. Cancer Res 60:2611–5, 2000

    PubMed  CAS  Google Scholar 

  59. Turner BC, Gumbs AA, Carter D, et al: Cyclin D1 expression and early breast cancer recurrence following lumpectomy and radiation. Int J Radiat Oncol Biol Phys 47:1169–76, 2000

    Article  PubMed  CAS  Google Scholar 

  60. Kenny FS, Hui R, Musgrove EA, et al: Overexpression of cyclin D1 messenger RNA predicts for poor prognosis in estrogen receptor-positive breast cancer. Clin Cancer Res 5:2069–76, 1999

    PubMed  CAS  Google Scholar 

  61. Linderholm B, Tavelin B, Grankvist K, et al: Does vascular endothelial growth factor (VEGF) predict local relapse and survival in radiotherapy-treated node-negative breast cancer? Br J Cancer 81:727–32, 1999

    Article  PubMed  CAS  Google Scholar 

  62. Wu Y, Saldana L, Chillar RV: Plasma vascular endothelial growth factor is useful in assessing progression of breast cancer post surgery and during adjuvant treatment. Int J Oncol 20:509–16, 2002

    PubMed  Google Scholar 

  63. Knoop A, Andreasen PA, Andersen JA, et al: Prognostic significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in primary breast cancer. Br J Cancer 77:932–40, 1998

    PubMed  CAS  Google Scholar 

  64. Haffty BG, Harrold E, Khan AJ, et al: Outcome of conservatively managed early-onset breast cancer by BRCA1/2 status. Lancet 359:1471–7, 2002

    Article  PubMed  Google Scholar 

  65. Pierce LJ, Strawderman M, Narod SA, et al: Effect of radiotherapy after breast-conserving treatment in women with breast cancer and germline BRCA1/2 mutations. J Clin Oncol 18:3360–9, 2000

    PubMed  CAS  Google Scholar 

  66. Gaffney DK, Brohet RM, Lewis CM, et al: Response to radiation therapy and prognosis in breast cancer patients with BRCA1 and BRCA2 mutations. Radiother Oncol 47:129–36, 1998

    Article  PubMed  CAS  Google Scholar 

  67. Verhoog LC, Brekelmans CT, Seynaeve C, et al: Survival in hereditary breast cancer associated with germline mutations of BRCA2. J Clin Oncol 17:3396–402, 1999

    PubMed  CAS  Google Scholar 

  68. Turner BC, Glazer PM, Haffty BG: BRCA1/BRCA2 in breast-conserving therapy. J Clin Oncol 17:3689, 1999

    PubMed  CAS  Google Scholar 

  69. Robson M, Levin D, Federici M, et al: Breast conservation therapy for invasive breast cancer in Ashkenazi women with BRCA gene founder mutations. J Natl Cancer Inst 91:2112–7, 1999

    Article  PubMed  CAS  Google Scholar 

  70. Robson ME, Chappuis PO, Satagopan J, et al: A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment. Breast Cancer Res 6:R8–R17, 2004

    Article  PubMed  CAS  Google Scholar 

  71. Pierce L, Levin A, Rebbeck T: Ten-year outcome of breast conserving surgery and radiotherapy in women with breast cancer and germline BRCA1/2 mutations: results from an international collaboration. Proceedings 26th Annual San Antonio Breast Cancer Symposium, 2003

    Google Scholar 

  72. Bremer M, Doerk T, Sohn C: Local relapse after postoperative radiotherapy in patients with bilateral breast cancer. Proceedings ASCO 22:42, 2003

    Google Scholar 

  73. Seynaeve C, Verhoog LC, Van De Bosch LM, et al: Ipsilateral breast tumour recurrence in hereditary breast cancer following breast-conserving therapy. Eur J Cancer 40:1150–8, 2004

    Article  PubMed  CAS  Google Scholar 

  74. Delaloge S, Kloos I, DAriane: Young age is the major predictor of local relapse among conservatively treated BRCA1 BRCA2 or non BRCA-linked hereditary breast cancer. Proceedings ASCO 22:41, 2003

    Google Scholar 

  75. Bougeard G, Limacher JM, Martin C, et al: Detection of 11 germline inactivating TP53 mutations and absence of TP63 and HCHK2 mutations in 17 French families with Li-Fraumeni or Li-Fraumeni-like syndrome. J Med Genet 38:253–7, 2001

    Article  PubMed  CAS  Google Scholar 

  76. Limacher JM, Frebourg T, Natarajan-Ame S, et al: Two metachronous tumors in the radiotherapy fields of a patient with Li-Fraumeni syndrome. Int J Cancer 96:238–42, 2001

    Article  PubMed  CAS  Google Scholar 

  77. Oppitz U, Bernthaler U, Schindler D, et al: Sequence analysis of the ATM gene in 20 patients with RTOG grade 3 or 4 acute and/or late tissue radiation side effects. Int J Radiat Oncol Biol Phys 44:981–8, 1999

    Article  PubMed  CAS  Google Scholar 

  78. Iannuzzi CM, Atencio DP, Green S, et al: ATM mutations in female breast cancer patients predict for an increase in radiation-induced late effects. Int J Radiat Oncol Biol Phys 52:606–13, 2002

    Article  PubMed  CAS  Google Scholar 

  79. Varghese S, Schmidt-Ullrich RK, Dritschilo A, et al: Enhanced radiation late effects and cellular radiation sensitivity in an ATM heterozygous breast cancer patient. Radiat Oncol Investig 7:231–7, 1999

    Article  PubMed  CAS  Google Scholar 

  80. Fisher BJ, Perera FE, Cooke AL, et al: Long-term follow-up of axillary node-positive breast cancer patients receiving adjuvant tamoxifen alone: patterns of recurrence. Int J Radiat Oncol Biol Phys 42:117–23, 1998

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, The Cancer Institute of New Jersey, 195 Little Albany Street, New Brunswick, NJ, 08903, USA

    Bruce G. Haffty

Authors
  1. Bruce G. Haffty
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Dept. of Medical Oncology, Jules Bordet Institute, Boulevard de Waterloo, 215, 1000, Brussels, Belgium

    Martine J. Piccart MD, PhD  & Fatima Cardoso MD  & 

  2. Anderson Cancer Center, The University of Texas MD, 1515 Holcombe Blvd, Houston, TX, 77030-4095, USA

    Mien-Chie Hung PhD

  3. Dept. of Radiation Oncology, Hospital of the University of Pennsylvania, 3400 Spruce Street, Philadelphia, Pennsylvania, 19104-4283, USA

    Lawrence J. Solin MD

  4. Dept. of Surgery, Emory University Hospital, 1364 Clifton Road NE B206, Atlanta, Georgia, 30322-1059, USA

    William C. Wood MD

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Haffty, B.G. (2006). Breast Cancer Management in the Era of Molecular Medicine: Tailored Radiotherapy — Clinical and Biological Aspects. In: Piccart, M.J., Hung, MC., Solin, L.J., Cardoso, F., Wood, W.C. (eds) Breast Cancer and Molecular Medicine. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-28266-2_13

Download citation

  • DOI: https://doi.org/10.1007/978-3-540-28266-2_13

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-28265-5

  • Online ISBN: 978-3-540-28266-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation